Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Health 2, 4349 Martin Luther King Boulevard, Houston, TX, 77204-5037, USA.
Sci Rep. 2023 Mar 15;13(1):4277. doi: 10.1038/s41598-023-31454-6.
Proteinuria is a risk factor for and consequence of kidney injury. Angiotensin II type 2 receptor (ATR) is an emerging reno-protective target and is anti-proteinuric under pathological conditions, including high salt-fed obese animals. However, the mechanisms remain unknown, particularly whether the anti-proteinuric activity of ATR is independent of its anti-hypertensive and anti-inflammatory effects. In the present study, obese Zucker rats were fed high sodium (4%) diet (HSD) for 48 h, a time in which blood pressure does not change. HSD caused proteinuria without affecting glomerular slit diaphragm proteins (nephrin and podocin), glomerular filtration rate, inflammatory and fibrotic markers (TNFα, IL-6, and TGF-β), ruling out glomerular injury, inflammation and fibrosis but indicating tubular mechanisms of proteinuria. At cellular and molecular levels, we observed a glycogen synthase kinase (GSK)-3β-mediated megalin phosphorylation, and its subsequent endocytosis and lysosomal degradation in HSD-fed rat kidneys. Megalin is a major proximal tubular endocytic protein transporter. The ATR agonist C21 (0.3 mg/kg/day, i.p.) administration prevented proteinuria and rescued megalin surface expression potentially by activating Akt-mediated phosphorylation and inactivation of GSK-3β in HSD-fed rat kidneys. Overall, ATR has a direct anti-proteinuric activity, potentially via megalin regulation, and is suggested as a novel target to limit kidney injury.
蛋白尿是肾脏损伤的一个风险因素和结果。血管紧张素 II 型受体(ATR)是一个新兴的肾脏保护靶点,在病理条件下具有抗蛋白尿作用,包括高盐喂养的肥胖动物。然而,其机制尚不清楚,特别是 ATR 的抗蛋白尿活性是否独立于其降压和抗炎作用。在本研究中,肥胖 Zucker 大鼠给予高盐(4%)饮食(HSD)48 小时,在此期间血压没有变化。HSD 导致蛋白尿,而不影响肾小球裂孔隔膜蛋白(nephrin 和 podocin)、肾小球滤过率、炎症和纤维化标志物(TNFα、IL-6 和 TGF-β),排除了肾小球损伤、炎症和纤维化,但表明存在肾小管蛋白尿机制。在细胞和分子水平上,我们观察到 HSD 喂养大鼠肾脏中糖原合酶激酶(GSK)-3β介导的 megalin 磷酸化及其随后的内吞作用和溶酶体降解。Megalin 是一种主要的近端肾小管内吞蛋白转运体。ATR 激动剂 C21(0.3mg/kg/天,ip)给药可预防蛋白尿,并通过在 HSD 喂养大鼠肾脏中激活 Akt 介导的磷酸化和 GSK-3β失活来挽救 megalin 表面表达,从而发挥抗蛋白尿作用。总的来说,ATR 具有直接的抗蛋白尿活性,可能通过 megalin 调节,提示其是限制肾脏损伤的一个新靶点。